TNF inhibitor

There have been big advances in the treatment of axial spondyloarthritis (AxSpA) in the last decade. Biologic drugs that target TNF and IL-17 have become mainstay treatments in AxSpA if the disease…

As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. There are three areas that always draw my attention each conference and…

New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a…